235980.Kq

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 11,997,347,140, which is significantly higher than its total liabilities of KRW 2,681,222,550, resulting in a current ratio of 32.86. The price-to-book ratio of 2.91 suggests that the market values the company at a premium relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized.

Profitability metrics are negative, with a return on equity of -27.86% and a return on assets of -26.33%, both significantly below the industry median for biotechnology firms. The company reported a net loss of KRW 12,810,783,520 and an operating loss of KRW 13,879,827,120, which is a concern for investors expecting positive returns.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher operational and market risks.

The company's growth trajectory is uncertain, with no outlook data provided for the current or next fiscal year. Historical revenue of KRW 3,898,477,870 does not provide a clear indication of future performance, and the absence of a defined growth strategy or market expansion plans is a concern for long-term investors.

Risk factors include a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.04 indicates a conservative capital structure, and the absence of significant long-term debt reduces financial leverage risk.

Recent events include the latest financial filing, which disclosed the company's financial position and performance. No recent earnings call transcripts or material events were identified in the available data, limiting the ability to assess management's strategic direction or operational updates.